Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2022-03-15 00:00:00 ET · period of report 2022-03-15 · accession 0001214659-22-003986 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-15 | 2022-03-15 | ALZN | McGrath Lynne Fahey | Dir | M - OptEx | $0.00 | +50.0K | 100.0K | +100% | $0 |
| D | 2022-03-15 | 2022-03-15 | ALZN | McGrath Lynne Fahey | Dir | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-15 | M | A | 50,000 | $0.00 | 100,000 | D | — | — | |
| 2 | Derivative | Restricted Stock Grant | 2022-03-15 | M | D | 50,000 | $0.00 | 0 | D | — · — to 2022-03-15 | 50,000 Common Stock | (F2) Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. (F3) 2,778 and 47,222 restricted shares previously vested on September 13, 2021 and October 13, 2021, respectively, with the final 50,000 shares of restricted stock vesting on March 15, 2022. |